CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS WITH GAIN CHROMOSOME 1q AT BLOOD TRANSFUSION AND HEMATOLOGY HOSPITAL

Trần Thùy Anh1,2, Phạm Kim Thạnh2, Nguyễn Tấn Bỉnh3, Phan Thị Xinh1,2,
1 Blood Transfusion Haematology Hospital
2 University of Medicine and Pharmacy at Ho Chi Minh City
3 Pham Ngoc Thach University of Medicine, Ho Chi Minh City

Main Article Content

Abstract

Objectives: describe characteristics of clinical symptoms, laboratory values at diagnosis and genetic features in multiple myeloma patients with amplification of chromosome 1q. Methods: cross-sectional descriptive studies are retrospective. Subjects: 95 patients newly diagnosed with multiple myeloma were included in this study at Blood transfusion hematology hospital from January 2017 to December 2020. Results: the frequency of patients with chromosome 1q amplification was 29,5% (n = 28). Among the clinical abnormalities, anemia and bone pain were the most common (>70%). There were no difference between patients with and without 1q amplification in plasmacytoma, weight loss, fever and hemorrhage. However, hypercalcaemia, Beta-2-microglobulin level, late stage of disease, multiple chromosomal abnormalities and high-risk genetic abnormalities were significant difference between 2 groups (p < 0.05). Conclusion: There are differences in the biological characteristics of the patients with chromosome 1q amplification, indicating that this group of patients belongs to the high-risk group.

Article Details

References

1. Chen D., Zhou D., Xu J., et al. (2019), "Prognostic Value of 1q21 Gain in Multiple Myeloma", Clin Lymphoma Myeloma Leuk, 19 (3), pp. e159-e164.
2. Bladé J., de Larrea C. F., Rosiñol L. (2012), "Extramedullary involvement in multiple myeloma", Haematologica, 97 (11), pp. 1618.
3. Fabris S., Ronchetti D., Agnelli L., et al. (2007), "Transcriptional features of multiple myeloma patients with chromosome 1q gain", Leukemia, 21 (5), pp. 1113-1116.
4. Grzasko N., Hajek R., Hus M., et al. (2017), "Chromosome 1 amplification has similar prognostic value to del (17p13) and t (4; 14)(p16; q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group", Leukemia & lymphoma, 58 (9), pp. 2089-2100.
5. Karim K. J., Hassan A. M., Getta H. A., et al. (2020), "Frequency and prognostic significance of hypercalcemia in patients with multiple myeloma", Medical Journal of Babylon, 17 (4), pp. 327.
6. Kenneth Kaushansky M., MACP, Marshall A. Lichtman M., Josef T. Prchal M., et al. (2016), "Williams Hematology 9th", Part XI (107), pp. 1733 - 1747.
7. Kyle R. A., Gertz M. A., Witzig T. E., et al., "Review of 1027 patients with newly diagnosed multiple myeloma". in Mayo Clinic Proceedings. 2003. Elsevier.
8. Rossi D., Fangazio M., De Paoli L., et al. (2010), "Beta‐2‐microglobulin is an independent predictor of progression in asymptomatic multiple myeloma", Cancer, 116 (9), pp. 2188-2200.